Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis

Int Urol Nephrol. 2020 Apr;52(4):791-802. doi: 10.1007/s11255-020-02418-w. Epub 2020 Mar 13.

Abstract

Background: The aim of this meta-analysis is to explore the effect of IL-2RA vs rATG on the rate of acute rejection, post-transplant infections, and graft as well as patient's survival in standard- and high-risk renal transplant patients receiving tacrolimus-based maintenance immunotherapy.

Methods: Random effects model was the method used for identifying risk difference. Confidence interval including the value 1 was used as evidence for statistically significant risk difference. Heterogeneity was assessed using Der Simonian analysis. Heterogeneity was evident at the level of P value < 0.1 RESULTS: The random effects model showed no significant differences in both acute rejection rates between IL-2RA and rATG induction therapies with relative risk of 1.24 graft survival with relative risk 0.90. Patient survival also did not demonstrate any significant difference with a relative risk of 1.19. Random effects for CMV infection showed a lesser tendency for CMV infection in IL-2RA group compared to ATG group the with a relative risk of 0.73.In subgroup analysis, the random effects model for acute rejection rates in high-risk transplants showed a higher risk of acute rejection in the IL-2RA group compared to rATG (relative risk equals 1.55) In standard-risk transplants, there were no significant differences between both groups with relative risk equals 1.02 CONCLUSIONS: This meta-analysis revealed no significant difference in patient and graft survival when using IL-2RA vs rATG with the tacrolimus-based maintenance immunosuppression era. However, subgroup analysis showed less incidence of rejection in high-risk renal transplant recipient's population using rATG compared to IL-2RA.

Keywords: Calcineurin inhibitors; Induction therapy; Outcomes; Renal transplant; Tacrolimus.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Antilymphocyte Serum / adverse effects
  • Antilymphocyte Serum / therapeutic use*
  • Basiliximab / therapeutic use*
  • Cytomegalovirus Infections / chemically induced
  • Daclizumab / therapeutic use*
  • Graft Rejection / prevention & control*
  • Graft Survival
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Induction Chemotherapy / methods*
  • Kidney Transplantation
  • Maintenance Chemotherapy
  • Models, Statistical
  • Receptors, Interleukin-2 / antagonists & inhibitors
  • Survival Rate
  • Tacrolimus / therapeutic use

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Receptors, Interleukin-2
  • Basiliximab
  • Daclizumab
  • thymoglobulin
  • Tacrolimus